Tasly Capital

Tasly Capital operates as the corporate venture and private equity vehicle for Tasly Holding Group, a major Chinese pharmaceutical company. It deploys from the parent's corporate treasury and invests for strategic alignment alongside financial returns, rather than managing third-party LP capital in a traditional blind-pool structure. Its mandate is tied directly to Tasly Holding's commercial and R&D priorities.

The firm spans early-stage venture through PIPE deals, with an emphasis on expansion and late-stage growth where commercial acceleration matters most. It writes checks to companies whose products or technologies can be scaled through the parent's manufacturing, distribution, and hospital network — a posture that favors assets approaching regulatory approval or market entry over pre-clinical science.

Healthcare dominates: biotech, medical devices, diagnostics, and digital health platforms in particular. The firm also evaluates enterprise software serving clinical workflows and select consumer-health adjacencies that fit the parent's commercialization infrastructure. Pure-play tech or sectors outside healthcare get screened for whether Tasly Holding's physical and regulatory capabilities meaningfully advantage the portfolio company.